Titan Pharmaceuticals, Inc.
TTNP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $10 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $5 |
| % Margin | – | – | – | 50% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $657 | $534 | $666 |
| SG&A Expenses | $777 | $657 | $534 | $666 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $777 | $657 | $534 | $666 |
| Operating Income | -$777 | -$657 | -$534 | -$666 |
| % Margin | – | – | – | -6,660% |
| Other Income/Exp. Net | -$26 | -$32 | -$29 | -$124 |
| Pre-Tax Income | -$803 | -$689 | -$563 | -$790 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$803 | -$689 | -$563 | -$790 |
| % Margin | – | – | – | -7,900% |
| EPS | -0.57 | -0.65 | -0.62 | -0.88 |
| % Growth | 12.3% | -4.8% | 29.5% | – |
| EPS Diluted | -0.57 | -0.65 | -0.62 | -0.88 |
| Weighted Avg Shares Out | 1,398 | 1,065 | 914 | 899 |
| Weighted Avg Shares Out Dil | 1,398 | 1,065 | 914 | 899 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$803 | -$657 | -$534 | -$666 |
| % Margin | – | – | – | -6,660% |